Medscape8h
Despite Early Promise GLP-1 Disappoints in Parkinson’s Disease
Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...
Hosted on MSN21h
GLP-1 Trends by CivicScience: GLP-1 Users Foresee Long-Term Use, Spending More on Clothing and Groceries, Plus More
This is just a tiny glimpse of the data available to CivicScience clients. Discover more data. CivicScience has data on over ...
FiercePharma1d
Nephrologists already aboard GLP-1 bandwagon, providing launchpad for Ozempic in CKD: Spherix
Nephrologists jumped on the GLP-1 bandwagon well before Novo Nordisk won FDA approval for Ozempic in chronic kidney disease ...
GLP-1 Users Are Spending Way Less on Groceries and Fast Food, According to a New Study
Snack foods and sweet treats have seen a decline in purchases, as people reach for more nutrient-dense options.
Medscape4h
Considerations for Prescribing GLP-1s Get More Complicated
New research explores the wide world of the positives, and potential drawbacks, of new obesity medications. And each brings a new consideration for physicians.
Medicine Buffalo1d
Ophthalmic complications in patients on antidiabetic GLP-1 medications are concerning neuro-ophthalmologists
A small percentage of patients taking GLP-1 medications have experienced vision problems, but a direct causal link with the ...
WPSD Local 620h
The benefits and risks of GLP-1 drugs
They're known to aid in blood sugar control and, now, weight loss — but, according to a sweeping new study, the popular GLP-1 ...
Healio1d
GLP-1 does not slow Parkinson’s disease progression in phase 3 study
Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...
How Eli Lilly is approaching GLP-1 marketing and what’s next
Eli Lilly Chief Corporate Brand Officer Lina Polimeni on how the brand differentiates itself in the crowded pharma market, ...
Whose cardiovascular health do SGLT2, GLP-1 diabetes drugs benefit most?
A recent review shows who newer medications for type 2 diabetes may help the most, particularly in reducing the risk of cardiovascular disease.
News Medical on MSN2d
High discontinuation rates of GLP-1 agonists found among patients with obesity
Discontinuation of GLP-1 receptor agonists in obesity is common, driven by weight regain and socioeconomic factors, impacting ...
Will This New GLP-1 Drug be More Powerful Than Ozempic?
CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.